Detalhe da pesquisa
1.
Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma.
Biol Blood Marrow Transplant
; 25(12): 2522-2526, 2019 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31525493
2.
Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results.
Biol Blood Marrow Transplant
; 25(5): 955-964, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30605731
3.
Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.
Biol Blood Marrow Transplant
; 25(4): 699-711, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30423480
4.
Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors.
Haematologica
; 104(4): 844-854, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30381298
5.
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome.
Biol Blood Marrow Transplant
; 23(5): 776-781, 2017 May.
Artigo
Inglês
| MEDLINE | ID: mdl-28108271
6.
Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.
Biol Blood Marrow Transplant
; 22(6): 1141-1144, 2016 06.
Artigo
Inglês
| MEDLINE | ID: mdl-26995694
7.
Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 22(9): 1588-1595, 2016 09.
Artigo
Inglês
| MEDLINE | ID: mdl-27343718
8.
Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.
Biol Blood Marrow Transplant
; 21(3): 552-8, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25528388
9.
Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort.
Biol Blood Marrow Transplant
; 21(4): 640-5, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-25528390
10.
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.
Blood
; 122(24): 3863-70, 2013 Dec 05.
Artigo
Inglês
| MEDLINE | ID: mdl-24065243
11.
Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
Blood
; 119(1): 296-307, 2012 Jan 05.
Artigo
Inglês
| MEDLINE | ID: mdl-22010102
12.
Clonal hematopoiesis-derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders.
Leukemia
; 2024 Apr 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38684821
13.
Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
Biol Blood Marrow Transplant
; 19(4): 670-5, 2013 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-23333777
14.
Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research.
Biol Blood Marrow Transplant
; 19(7): 1102-8, 2013 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-23632091
15.
Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement.
Br J Haematol
; 162(5): 648-56, 2013 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-23829536
16.
Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease.
Blood
; 118(16): 4472-9, 2011 Oct 20.
Artigo
Inglês
| MEDLINE | ID: mdl-21878671
17.
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.
Blood
; 117(24): 6714-20, 2011 Jun 16.
Artigo
Inglês
| MEDLINE | ID: mdl-21493797
18.
Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.
Am J Hematol
; 88(12): 1017-23, 2013 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-23907769
19.
Risk factors for 30-day hospital readmission following myeloablative allogeneic hematopoietic cell transplantation (allo-HCT).
Biol Blood Marrow Transplant
; 18(6): 874-80, 2012 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-22040844
20.
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Biol Blood Marrow Transplant
; 18(10): 1564-72, 2012 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-22683613